When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Python vs. Kotlin: Side-by-side code comparison How does the snake stack up against a new-school JVM language? Prepare to be surprised (video). Hands-on with the new sampling profiler in Python 3.15 ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Is Mojo still a contender for Python’s data science crown? AI and machine learning outside of Python There’s no question Python is the default choice for machine learning and data science. That ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

What’s the best way to bring your AI agent ideas to life: a sleek, no-code platform or the raw power of a programming language? It’s a question that sparks debate among developers, entrepreneurs, and ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Transaction value is based on the SEC Form 4 weighted average purchase price ($6.04) as reported for the transaction on October 10, 2025. How does the scale of this transaction compare to Christopher ...